BioAtla (BCAB) Stock Price, News & Analysis

Company Overview

BioAtla, Inc. was a biotechnology company focused on developing antibody-based cancer therapies. The company’s research centered on its Conditionally Active Biologics (CAB) platform, which was designed to create therapeutic antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissue.

BioAtla’s development pipeline included antibody-drug conjugates and other immuno-oncology candidates. Its leading programs included mecbotamab vedotin, also known as BA3011, an antibody-drug conjugate targeting AXL, and ozuriftamab vedotin, or BA3021, an antibody-drug conjugate directed at ROR2. The company evaluated these candidates in clinical studies for solid tumors and other cancers.

Founded in 2007 and headquartered in San Diego, California, BioAtla advanced its programs through clinical development and collaborations intended to support the development of targeted cancer medicines. The company later reduced operations and pursued strategic alternatives after encountering clinical and financial challenges. Public disclosures indicated that BioAtla ultimately wound down its business, so its historical pipeline and platform provide the primary basis for describing the company.

Key Stats

• Today's Range: $1.25 to $1.30
• 50-Day Range: $1.08 to $3.50
• 52-Week Range: $1.07 to $71.50
• Volume: 3,911 shs
• Average Volume: 53,084 shs
• Market Capitalization: $2.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.00
• Consensus Rating: Hold

BioAtla Stock Analysis - MarketRank™

BioAtla scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

BioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

BioAtla has a consensus price target of $200.00, representing about 15,284.6% upside from its current price of $1.30.

Amount of Analyst Coverage

BioAtla has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioAtla is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioAtla is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BCAB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAtla does not currently pay a dividend.

Dividend Growth

BioAtla does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAtla insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.34% of the stock of BioAtla is held by insiders.

Percentage Held by Institutions

77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCAB
• CIK: 1826892
• Web: www.bioatla.com
• Phone: 858-558-0708
• Fax: N/A
• Employees: 60
• Year Founded: 2007

Price Target and Rating

• Average Price Target for BioAtla: $200.00
• High Price Target: $200.00
• Low Price Target: $200.00
• Potential Upside/Downside: +15,284.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($25.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.61 million
• Net Margins: N/A
• Pretax Margin: -370.05%
• Return on Equity: N/A
• Return on Assets: -289.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: $8.50 million
• Price / Sales: 0.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($28.51) per share
• Price / Book: -0.05

Miscellaneous

• Outstanding Shares: 1,666,000
• Free Float: 1,510,000
• Market Cap: $2.17 million
• Optionable: Optionable
• Beta: 0.64